PTC Therapeutics, a developer of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes, registered for an IPO Friday evening. Morgan Stanley, JPMorgan and Pacific Growth Equities will underwrite the deal. Terms and timing have yet to be disclosed.
